Takeda Pharmaceutical Company - TAK Earnings per share for the last 12 months

Public company logo of Takeda Pharma (TAK)

Analyzing the percentage change in trailing twelve-month EPS dynamics on GURU.Markets, we note that -11.90 serves as the base value for this parameter. Takeda Pharmaceutical (TAK) shares are under pressure due to debt following acquisition deals and generic risks. Price reductions mandated by the Japanese regulator are limiting profit growth. Business stability is maintained by outsourcing early-stage research to external CRO partners.

TAK Takeda Pharmaceutical Company: Earnings per share for the last twelve months in the range 02/11/2024 - 11/18/2026

Financial and market metric breakdowns for Takeda Pharmaceutical Company Limited (TAK)

- share price and expert price forecast:
Fundamental company valuation:TAK - Takeda Pharmaceutical Company
Signature product of Takeda Pharmaceutical Company

The EPS TTM YoY dynamics mathematically reflect the efficiency of converting operating revenue into net income per share over a rolling year. This indicator measures the actual speed of profitability recovery while excluding one-off distortions. For Takeda Pharmaceutical (TAK), this calculation is critical due to pricing pressure from Japanese regulators and patent expirations. By analyzing the current EPS TTM YoY growth rate, investors assess the ecosystem's ability to offset losses from legacy blockbusters with new drugs.